Background: Chronic obstructive pulmonary disease (COPD), is a very common disease of respiratory system. An increasing number of clinical trials on Yupingfeng formula in the management of stable COPD have been performed. However, the evidence base for it remains unknown. This review aims at assessing the efficacy, and safety of modified Yupingfeng formula in the treatment of stable COPD through a systematic review of all available randomized controlled trials. Materials and Methods: Literature retrieval was conducted using four English databases (CENTRAL, PubMed, EMBASE, and ISI Web of Science), and four Chinese databases (CBM, CNKI, VIP, and WANFANG), from respective inception to January 2013, and supplemented with a manual search. Review authors independently extracted the trial data, and assessed the quality of each trial. Methodological quality was assessed by Cochrane risk of bias and Jadad's scale. The following outcomes were evaluated: (1) lung function; (2) 6-minute walk distance (6MWD); (3) effective rate; (4) serum levels of IgA, IgG and IgE; and (5) Conclusions: Within the limitations of this systematic review, we may conclude that compared with Western medications alone, Yupingfeng formula, when combined with Western medications can provide more benefits for patients with stable COPD, without any serious adverse reactions being identified. However, these benefits need to be further confirmed through high-quality prospective placebo-controlled trials that should be strictly conducted in accordance with methodological principles and procedures.
Introduction
Chronic obstructive pulmonary disease (COPD), is a common preventable disease characterized by persistent airflow limitation that is usually progressive. Although it can be properly managed, [COPD] , is said to be one of the leading cause with high morbidity and mortality rates globally, resulting into an economic, and social burden that is both substantial and increasing. It ranked sixth as a major cause of death in 1990, and it is estimated that COPD will become the fourth leading cause of death globally by 2030. The prevalence and associated socio-economic burdens of COPD are projected to increase in the coming decades (Gold members, 2013).
Conventional therapy for stable COPD is aimed at relieving symptoms, reducing long-term lung function decline, preventing exacerbations, and improving health status and exercise tolerance. The management steps of COPD includes smoking cessation, oxygen therapy, physical activity, pulmonary rehabilitation, nutritional supplementation, vaccinations, and the use of inhaled corticosteroids, long-acting bronchodilators, or combination of corticosteroid and bronchodilator therapy if necessary (Qaseem et al., 2011) . However, COPD is a progressive disease leading to a decrease in lung function over time with the best available care. Till date, none of the existing Western medications for COPD has been conclusively shown to modify the long-term decline in lung function (Gold members, 2013). Unsatisfactory treatment response from conventional Western drugs contributes to the increasing popularity of Traditional Chinese Medicine (TCM).
TCM has its potential advantages different from modern medicines, and is recognized as an attractive alternative to conventional Western medicine. There is a long history in the use of TCM in treating respiratory diseases, particularly in China, Japan, and other Asian countries (Sorkness et al., 2009 ). According to the TCM theory, COPD should be classified in the category of syndrome characterized by dyspnea and cough. From the standpoint of TCM patients, COPD usually manifest with Qi-deficiency syndrome (Fu et al., 2007) . In TCM, Qi is one of the most important substances in the body, and it spreads over the whole body via its dispersing and descending functions. When the Qi is too weak to control the pores and protect the body, the patient is more susceptible to catching a cold (Yang et al., 2010; Dowie et al., 2009 ), which commonly leads to acute exacerbations of COPD. Therefore, the treatment principle of COPD should focus on nourishing Qi. Previous clinical studies have demonstrated ginseng or combined with other herbs can improve the lung function of patients with COPD .
Yupingfeng formula (Gyokuheifu-san in Japanese, Jade Windscreen Powder in English), originally recorded in the book Danxi Xinfa, is a classical TCM formula consisting of three herbal medicines, i.e. Huang Qi (Astragalus membranaceus); Bai Zhu (Rhizoma atractylodis macrocephalae); and Fang Feng (Radix saposhnikoviae). Huang Qi is a powerful medicine for strengthening Qi of spleen and lung to activate body energy as well as to protect the body form external pathogens. Bai Zhu strengthens spleen, which is the source of Qi. Fang Feng can benefit the defensive Qi, and consolidate the exterior. By combining these three herbal medicines, Yupingfeng formula has the potential to invigorate Qi and consolidate the superficial resistance, which may increase a patient's ability to protect himself from invasion by external pathogenic influence (Makino et al., 2004) . It is frequently used for treating spontaneous sweating, aversion to wind, weakness and a susceptibility to catching colds. Moreover, it has been widely prescribed for hundreds of years to prevent or treat respiratory tract diseases, such as perennial allergic rhinitis, respiratory infections, bronchial asthma, and COPD when present as Qi-deficiency syndrome (Fang et al., 2005) . Increasing efforts have been directed towards seeking for relevant scientific evidence, and an increasing number of clinical trials on Yupingfeng formula in the management of COPD have been performed, but the findings have not yet been systematically summarized.
The purpose of the current systematic review was to assess the efficacy and safety of modified Yupingfeng formula in the treatment of COPD through a systematic collection of evidence from randomized controlled trials (RCTs). It was expected that, this systematic review could provide more evidence-based information for real-world clinical practice.
Methods

Criteria for considering studies for this review Types of studies
Only [RCTs], were eligible for this review, irrespective of blinding. Quasi-randomized and nonrandomized controlled trials were not considered.
Types of participants
We reviewed studies of adults with COPD defined as progressive chronic air-flow limitation evident by spirometry with a post-bronchodilator FEV 1 /FVC ratio < 70%, regardless of smoking history. Patients were in a clinically stable state at the start of the study, without recent exacerbation, hospitalization or, any need for antibiotics nor systemic corticosteroids. Patients did not have any clinical features of asthma.
Types of interventions
A comparative study between Yupingfeng formulas or, when combined with Western medications, and placebo; no treatment or, same Western medications as controls were included. In clinical practice of TCM, it is common to modify original formula by adding or substituting herbs in accordance with a patient's syndrome to enhance the efficacy of the original formula. Thus, any form of administration of Yupingfeng formula or its modified prescription such as decoction, capsule, tablet, pill, and powder was acceptable for inclusion in the review. Papers were excluded when Chinese herbs or other TCM therapies were used in the control group.
Types of outcome measures
The primary outcome measure was lung function. Secondary outcomes included: (1) exercise capacity (6-minute walk distance, 6MWD); (2) effective rate defined as the symptoms scores reduced rate (cough, cough-up phlegm, dyspnea, wheezing or other lung symptoms) ≥ 30% according to the Chinese criteria "Guiding In addition, a manual search of ten leading TCM journals was performed to identify other potentially relevant studies. Meanwhile, we also searched the reference lists of review articles and identified RCTs for any possible titles matching the inclusion criteria. Furthermore, we contacted experts in this field, and relevant pharmaceutical companies for other unpublished studies.
Search methods for identification of studies
Selection of studies
Two review authors (Yunqing Zhong and Xiufeng Wang), independently selected trials for inclusion by scanning the titles, abstract sections, and keywords of each study retrieved and the full-text articles if necessary. Agreement between review authors for inclusion of studies was recorded.
Data extraction and management
To avoid bias in the data extraction process, the review authors (Bing Mao and Wei Zhou) independently extracted data using a piloted data extraction form and compared the results. They were not blinded to study authors, institutions, or journals of publication. Details of participants, severity of COPD, COPD duration, study design, interventions, outcome measures and adverse events of each study were extracted. Any lack of information was supplemented by correspondence with the original principal investigators. Each entry was double-checked by both reviewers. All review authors participated in resolving discrepancies until a consensus was reached.
Quality assessment
Risk of bias was independently assessed by two review authors (Jie Min and Hongli Jiang), according to the criteria specified in the Cochrane Handbook for Systematic Reviews of Interventions 5.1.0 (Higgins et al., 2013) across six domains, i.e. sequence generation, allocation concealment, blinding, incomplete outcome data, selective outcome reporting and other potential sources of bias. Each domain was classified as having either a high, low, or unclear risk of bias. We also used the Jadad scoring system for quality assessment, which evaluates a study in terms of the description of randomization, blinding, and dropouts. The Jadad scale is a 5-point scale for assessing the quality of randomized trials in which three points or more indicate superior quality (Jadad et al., 1996) . Discrepancies were resolved by consensus. If required, a third party (Bing Mao) would be consulted. To avoid selection bias, no study was rejected because of these quality criteria.
Data synthesis
All calculations were conducted using STATA software (STATA version 12.0, StataCorps, College Station, Texas, USA). We performed the meta-analysis by pooling homogeneous studies. For dichotomous data, we presented results as relative risk (RR), with 95% confidence interval (CI). For continuous data, we calculated weighted mean difference (WMD) if outcomes were measured in a same way among trials or standardized mean difference (SMD) if outcomes were measured by different methods among trials. Heterogeneity between the trials was analyzed by Cochrane's Q test, and potential reasons for heterogeneity were also explored. If the analysis showed low heterogeneity (P ≥ 0.10 and I 2 ≤ 50%), data were synthesized using a fixed-effect model. Otherwise, a random-effects model was applied. Publication bias was assessed by Egger's and Begg's statistical tests and funnel plot if the meta-analysis included more than 10 trials (Sedgwick P., 2013). A two-tailed P value less than 0.05 was considered statistically significant.
Sensitivity analysis
We used STATA's METANINF command to investigate whether the exclusion of any one study would significantly change the pooled estimate, that is, whether the pooled point estimate with one study excluded would lie outside the 95% CI of the pooled estimate with all studies included. If the sensitivity analysis was close to the results of the complete study analysis, this strengthened the level of confidence.
Results
Description of studies
Figure 1: show the paper selection process, and exclusion reasons. A total of 76, potentially eligible citations were identified in the initial search, of which 45, were excluded because those were not relevant to the topic. Based on title and abstract, other 13, articles were further excluded for the following reasons: 2, review articles, and 11, animal studies. Two studies that were pre-post comparisons with no control group were also excluded. Of the remaining 16, articles, two additional trials which enrolled patients with acute exacerbations of COPD were further excluded. After careful examination of the retrieved articles, 4 were also excluded because other Chinese herbs were used as controls. One trial (Li et al., 2010) , was presented in two papers, therefore this was considered as one study. 
Characteristics of included trials
The main characteristics of the included trials are listed in Tables 1 and 2 . All of the identified studies involving a total of 660, stable COPD patients were conducted in China, and all articles were written in Chinese language. None of these was designed as a multicenter study. All trials were published in scientific journals, no unpublished dissertations or conference papers were included. All nine trials were parallel-design, randomized controlled trials. The publication years of these studies ranged from 2005, to 2012. The number of subjects included in each study ranged from 40-100. Eight studies (Huang et (Zhang et al., 2011) , explained by the following reasons: 2 patients in therapy A group suffered from COPD exacerbations, and 5 could not tolerate TCM; 4 patients in therapy B group withdrew due to COPD exacerbations, and 1 experienced a cerebrovascular accident.
Methodological quality Assessment of risk of bias
All the included studies claimed "randomization", but only three studies (Li et The baseline characteristics of the trial and control groups in the included trials were comparable. But none of the studies described any pre-calculated sample size, and information on early stopping was insufficient. Overall, the domain was rated as "unclear" in all studies. Detailed information is shown in Table 3 .
Assessment of Jadad's scale
Through reading the full text, all nine studies' level of evidence was graded scores lower than three according to the Jadad quality score. Table 2) . (Fig. 6) . The concentrations of serum IgA and IgG in stable COPD patients receiving therapy A were significantly higher than those receiving therapy B, and patients receiving therapy A were more likely to gain improvements in serum IgA, and IgG levels. But no difference was found in the serum IgE levels between the two groups, and there was no evidence that therapy A significantly altered the levels of serum IgE compared with therapy B.
Effects of interventions
Adverse events
One study (Huang et al., 2005) stated that two patients receiving therapy A experienced dry mouth and mild abdominal distension, and 1 subject receiving therapy B complained of loss of appetite. But all of these symptoms gradually disappeared after proper medical treatment. The remaining eight studies did not report any adverse events.
Publication bias
In general, if the number of studies is less than 10, a funnel plot is thought to be an unreliable method of investigating publication bias (Sedgwick, 2013) . Due to the insufficient number of included studies, a formal assessment of reporting bias by visual inspection of a funnel plot was not possible.
Sensitivity analysis
As shown in Figure 2 , the meta-analysis of FEV 1 revealed a relatively high degree of heterogeneity across the studies. We used STATA's METANINF command to examine the influence of an individual study on the pooled estimate (WMD) by excluding each study in turn. For example, rerunning the analysis without the study (Li et al., 2010) 
Discussion
Yupingfeng formula, a well-known traditional Chinese medicine, commonly used to treat the diseases of the respiratory system. The aim of this study was to provide a comprehensive systematic review to assess the efficacy and safety of modified Yupingfeng formula for patients with stable COPD. The results of review indicate that compared with Western medications alone, the use of Yupingfeng formula combined with Western medications could significantly improve lung function, 6MWD, and effective rate (the symptoms scores reduced rate), and increase the serum IgA and IgG levels, but no difference was found in the serum IgE levels between the two groups. Our current results indicate that Yupingfeng formula could significantly enhance the humoral immune function through the increase of serum levels of IgA and IgG. Based on the results of this review, conventional Western drugs given in combination with orally administered Yupingfeng formula seem superior to conventional Western drugs alone for patients with stable COPD. Also, as no significant adverse events were observed in the included studies, Yupingfeng formula appears to be well tolerated, even when combined with conventional Western medicine.
These findings are consistent with previous data. Makino et al., (2005a) found that Yupingfeng formula could stimulate immune responses when the antigen had already invaded the body, and that it might consolidate the resistance of nasal mucosa to protect from ovalbumin (OVA) invasion. Another study by Makino et al., (2004) showed that Yupingfeng formula had preventive and curative effects on allergic rhinitis induced with Japanese cedar pollens in guinea pig. Song et al., (2013) It is noteworthy that this review has several limitations. Firstly, as the definition of COPD has been changing over the years (Chhabra S.K., 2009), differences in definition of the disease may bias our search results. Although a comprehensive search strategy was adopted, we still cannot guarantee that all eligible trials have been identified. And we were also unable to use formal methods to determine if there was any publication bias as too few studies were available. The possibility that there are unpublished studies or other published studies that were not indexed in the electronic databases we searched cannot be excluded, because negative or no significant findings are less likely to be published (Dirnagl et al., 2010) . Secondly, the reporting of trial methods and procedures was unclear and insufficient. The majority of the 9 included studies suffered from methodological weaknesses based on the assessment of the Cochrane risk of bias and the Jadad's scale. The inadequacy of sequence generation, allocation concealment and blinding, and dropouts account were the major sources of potential bias. Low-quality trials are more likely to overestimate efficacy. Therefore, these results must be interpreted with caution. Thirdly, none of these studies was designed as a multicenter study. Most of the trials were of small sample size trials, and no studies estimated the sample size, which is essential for ensuring adequate sample size and statistical power to detecting clinical significant difference between interventions (Eng J., 2003; Scales et al., 2005) . Fourthly, for the purpose of evaluating effects of therapies, the test intervention should be compared with placebo (Shah K.N., 2009). However, no placebo-controlled trial has studied the efficacy and safety of Yupingfeng formula for stable COPD. Finally, although the safety profile of Yupingfeng formula has been demonstrated in this systematic review, we still cannot be assured of its safety because the small sample sizes might have limited power to detect rare adverse events.
Although the results of this review may be limited by the low quality of the included trials, the findings are promising, and further investigation into the efficacy and safety of Yupingfeng formula is worthy of merit. The methodological quality of clinical trials on Yupingfeng formula in the treatment of stable COPD needs to be further improved in accordance with the Consolidated Standards of Reporting Trials (CONSORT) statement, and the publication of protocols should be encouraged (Schulz et al., 2010; Gagnier et al., 2006) . In particular, large-scale, transnational cooperative, rigorously designed, multicenter, randomized, placebo-controlled, double-blind trials with explicit clinical and diagnostic criteria, sufficient duration of follow-up and description of all relevant clinical outcome measures are still warranted.
Conclusions
Within the limitations of this systematic review, we may conclude that compared with Western medications alone, combined Yupingfeng formula and Western medications can provide more benefits for patients with stable COPD, without any serious adverse reactions being identified. There is encouraging evidence suggesting that Yupingfeng formula may be a safe and effective herbal treatment option for patients with stable COPD. However, these benefits need to be further confirmed through high-quality prospective trials that should be strictly conducted in accordance with methodological principles and procedures.
